Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction

被引:27
作者
Dorsch, Michael P.
Lee, Jin Sun
Lynch, Donald R.
Dunn, Steven P.
Rodgers, Jo E.
Schwartz, Todd
Colby, Emily
Montague, Debbie
Smyth, Susan S.
机构
[1] Gill Heart Inst, Div Cardiovasc Med, Lexington, KY 40536 USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ Michigan Hosp & Hlth Ctr, Dept Pharm Serv, Ann Arbor, MI USA
[4] Univ N Carolina, Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[5] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA
关键词
aspirin resistance; coronary artery disease; myocardial infarction;
D O I
10.1345/aph.1H621
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Aspirin therapy is a cornerstone in the prevention of atherothrombotic events, but recurrent vascular events are estimated to occur in 8-18% of patients taking aspirin for secondary prevention after 2 years. Estimates of biologic aspirin resistance vary from 5% to 60%, depending on the assay used. However, the relationship between biologic measurements of aspirin resistance and adverse clinical events remains unclear. OBJECTIVE: To determine whether patients with documented myocardial infarction (MI) while on aspirin therapy (cases) were more likely to be aspirin resistant than were patients with coronary artery disease (CAD) who had no history of MI (controls) and to assess clinical predictors of aspirin resistance in patients with stable CAD. METHODS: This case-control study examined aspirin responses using the VerifyNow Aspirin Assay system in 50 cases and 50 controls who had taken a dose of aspirin within 48 hours of presentation to the clinic visit. Odds ratios were estimated to determine the association between aspirin resistance and Mi. Independent predictors of aspirin resistance were determined using univariate and multivariate analyses. RESULTS: An increase in the prevalence of aspirin resistance among cases (16% vs 12% in controls) was not observed (OR 1.40; 95% Cl 0.45 to 4.37; p = 0.566). In the overall CAD population, female sex was independently associated with aspirin resistance (OR 4.01; 95% Cl 1. 15 to 13.92; p = 0.029). CONCLUSIONS: Additional large studies are required to understand whether biologically defined aspirin resistance is associated with increased risk for cardiovascular events, with special attention paid to sex differences.
引用
收藏
页码:737 / 741
页数:5
相关论文
共 12 条
[1]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[2]   Sex differences in platelet reactivity and response to low-dose aspirin therapy [J].
Becker, DM ;
Segal, J ;
Vaidya, D ;
Yanek, LR ;
Herrera-Galeano, JE ;
Bray, PF ;
Moy, TF ;
Becker, LC ;
Faraday, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (12) :1420-1427
[3]   Aspirin for the primary prevention of cardiovascular events in women and men - A sex-specific meta-analysis of randomized controlled trials [J].
Berger, JS ;
Roncaglioni, MC ;
Avanzini, F ;
Pangrazzi, I ;
Tognoni, G ;
Brown, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (03) :306-313
[4]   Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment [J].
Chen, WH ;
Lee, PY ;
Ng, W ;
Tse, HF ;
Lau, CP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) :1122-1126
[5]  
Coleman J, 2004, POINT CARE, V3, P77, DOI DOI 10.1097/01.P0C.0000127153.41926.BA
[6]   DEVELOPMENT OF ASPIRIN RESISTANCE IN PERSONS WITH PREVIOUS ISCHEMIC STROKE [J].
HELGASON, CM ;
BOLIN, KM ;
HOFF, JA ;
WINKLER, SR ;
MANGAT, A ;
TORTORICE, KL ;
BRACE, LD .
STROKE, 1994, 25 (12) :2331-2336
[7]   Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases [J].
Jochmann, N ;
Stangl, K ;
Garbe, E ;
Baumann, G ;
Stangl, V .
EUROPEAN HEART JOURNAL, 2005, 26 (16) :1585-1595
[8]   Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study [J].
Kjeldsen, SE ;
Kolloch, RE ;
Leonetti, G ;
Mallion, JM ;
Zanchetti, A ;
Elmfeldt, D ;
Warnold, I ;
Hansson, L .
JOURNAL OF HYPERTENSION, 2000, 18 (05) :629-642
[9]   Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer [J].
Malinin, A ;
Spergling, M ;
Muhlestein, B ;
Steinhubl, S ;
Serebruany, V .
BLOOD COAGULATION & FIBRINOLYSIS, 2004, 15 (04) :295-301
[10]   Aspirin resistance: An evaluation of current evidence and measurement methods [J].
Martin, CP ;
Talbert, RL .
PHARMACOTHERAPY, 2005, 25 (07) :942-953